Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Immunological Efficacy of a Prime-boost Strategy Combining a 7-valent Pneumococcal Conjugate Vaccine (PCV) Followed by a 23-valent Pneumococcal Polysaccharide Vaccine (PPV) Versus PPV Alone in HIV-infected Adults. ANRS 114 PNEUMOVAC.

NCT00148824 is registered in ClinicalTrials.gov with ANRS, Emerging Infectious Diseases as lead sponsor.

NCT NCT00148824
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00148824 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Immunological Efficacy of a Prime-boost Strategy Combining a 7-valent Pneumococcal Conjugate Vaccine (PCV) Followed by a 23-valent Pneumococcal Polysaccharide Vaccine (PPV) Versus PPV Alone in HIV-infected Adults. ANRS 114 PNEUMOVAC.
Lead sponsor
ANRS, Emerging Infectious Diseases
Phase
Phase 2
Overall status
Completed
Start date
February 28, 2003
Completion date
January 31, 2006
Enrollment
212
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hiv infections